BCL2 and myelodysplastic syndrome: Although myelodysplastic syndrome (MDS) during progression to acute myeloid leukemia (AML) is indicated for hypomethylating therapy (HMA, 5-Azacytidine (AZA)), the addition of a BCL2 inhibitor (Venetoclax, VEN) yields significantly better responses in patients unsuitable for intensive chemotherapy.